speb/financial-data huggingface dataset:
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 6561482000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 12056488000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 50719105.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 488315000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 171068000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 11735241000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 185944000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 232287000.00
ORCHPHARMA.NS income_statement (quarterly, 2024-09-30) — Other Operating Expenses: 411414000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 6311278000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 2435895000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Payables: 2238247000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 50719105.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 12242432000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 12056488000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 8135000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 16351441000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 13501813000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 1649379000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 12242432000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 4109009000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 8017784000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 1297996000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 5522644000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — +Operating Expense: 1209064000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 311141000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — +Total Revenue: 9219259000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 2374787000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 2220921000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 2220921000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 2418321000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 2418321000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -7034352000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -7034352000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 8465180000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 8465180000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -365075000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -365075000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Amortization: 11306000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 11306000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 88619000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 88619000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 50715929.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 50669545.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Basic EPS: 19.65
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 4.40
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 36009000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 1874690000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 1874690000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -1501080000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 3700000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 3700000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 507191000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 507191000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 211068000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 211068000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 211227000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 211227000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 211068000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 211068000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -621454000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: 62158000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Payable: -67823000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -490660000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -1085329000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 175059000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock: 507191000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 507191000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 12672854000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 12672854000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 0.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 1263212000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 1263212000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 5442226000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 1380162000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Assets: 8074173000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 8074173000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 3333000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 3333000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt: 426033000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 426033000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 429366000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 429366000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Deferred Taxes Assets: 1012000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Deferred Taxes Assets: 1012000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 2855696000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 2855696000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 23660000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 23660000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation: 345458000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 345458000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 345458000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 88717000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 345458000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 88717000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 50715929.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 50669545.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Diluted EPS: 19.65
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 4.40
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 996568000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 222946000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — EBIT: 1101049000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — EBIT: 230091000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — EBITDA: 1446507000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — EBITDA: 318808000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — End Cash Position: 211068000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: 252217000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 1066157000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 1066157000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: -1308929000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: 3198000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 82009000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 170143000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 170143000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 2783396000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 2783396000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 14616764000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 14616764000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Gross Profit: 3777033000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 994625000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense: 145401000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 39150000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 145401000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 39150000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income: 172774000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 172774000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -31134000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 187386000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Inventory: 1981779000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 1981779000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 14415245000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 14415245000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -269309000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 88619000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 88619000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentsin Associatesat Cost: 408245000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Associatesat Cost: 408245000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 0.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 408163000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 408163000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 367000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 367000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 1316358000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 1316358000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 1316725000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 1316725000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 408245000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 408245000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 33872000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 33872000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 10904258000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 10904258000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: 0.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 0.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Debt: 1531323000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 1531323000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -58488000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Net Income: 996568000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income: 222946000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 996568000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 222946000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 996568000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 222946000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Discontinuous Operations: 0.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 996568000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 222946000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 996568000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 222946000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 994633000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 996568000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 222946000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Net Interest Income: -145401000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -39150000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 1044385000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 283351000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -2207000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -145401000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -39150000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: -8000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Net PPE: 7582412000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 7582412000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -1501080000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 285558000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 12502711000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 12502711000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 0.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 0.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 33872000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 33872000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 555555000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 555555000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 1446507000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 318808000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Normalized Income: 996568000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 222946000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 192151000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Operating Income: 2567969000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Income: 683484000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Operating Revenue: 9219259000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 2374787000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 50719105.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 50719105.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 1281936000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 1281936000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 33230000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 33230000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 685606000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 685606000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 170143000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 170143000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 29395000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 29395000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -27373000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 618319000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 618319000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: -1466920000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: -453393000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 898422000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Payable: 103986000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 103986000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Properties: 166441000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 166441000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 31377000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 31377000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 159000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 159000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Other Special Charges: 3198000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Payables: 2324907000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Payables: 2324907000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 23660000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 23660000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 563423000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 563423000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Pretax Income: 955648000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 190941000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: -69716000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: 0.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -1501080000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 886227000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 886227000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 5442226000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 1380162000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 345458000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 88717000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 18760000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 18760000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Research And Development: 83667000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 1585098000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 1585098000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: -20775673000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -20775673000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 0.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 241356000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 323365000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Share Issued: 50719105.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 50719105.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Special Income Charges: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 12672854000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 12672854000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 12502711000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 12502711000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Tax Provision: -1935000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Provision: -394000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.30
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.30
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 26729000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 26729000.00
ORCHPHARMA.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -9374000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Assets: 16879147000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 16879147000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 13989212000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 13989212000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Debt: 1746091000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 1746091000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 12672854000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 12672854000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Total Expenses: 6651290000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 1691303000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 4206293000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 4206293000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 8804974000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 8804974000.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 1350597000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 1350597000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 3941000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
ORCHPHARMA.NS balance_sheet (annual, 2025-03-31) — Working Capital: 5218477000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 5218477000.00
ORCHPHARMA.NS income_statement (annual, 2025-03-31) — Write Off: 138127000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 685423000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 1729288000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 50716327.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 2.94
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 988654000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 86541000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 86541000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 50716327.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 2.94
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 149106000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — EBIT: 169687000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — EBITDA: 256228000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 740634000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 32575000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 32575000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income: 149106000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 149106000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 137112000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Discontinuous Operations: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Extraordinary: 11994000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 137112000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 137112000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 149106000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -32575000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -32575000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 256228000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 137112000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Income: 55211000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 1729288000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 114476000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 382753000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 137112000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 988654000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 86541000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 1674077000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 713947000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 1935242000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 1489422000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 2021727000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 527834000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 50651327.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Basic EPS: -1.13
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 3700000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 507191000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 419872000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 1495764000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 507191000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 12738433000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 1203176000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 1325065000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 7046776000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 3700000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 472037000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 475737000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Deferred Taxes Assets: 2495000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 2101747000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 21785000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 89014000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 89014000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 50651327.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: -1.13
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -57236000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — EBIT: 3974000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — EBITDA: 92988000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 155648000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 7355419000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 610177000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 37323000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 37323000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 3062205000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 15550818000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 527834000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 0.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 2340348000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 2340348000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 39959000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 2392513000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income: -57236000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -57236000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -57236000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -57236000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -57236000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -57236000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -37323000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -37323000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 7355419000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 12582785000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 92988000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Normalized Income: -57236000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Operating Income: -103770000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 1935242000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 50719105.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 444691000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 114803000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 12231242000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 155648000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 1647693000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 107744000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 376427000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 6152243000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 1075892000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Payables: 1489422000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Pretax Income: -33349000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 1325065000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 89014000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 50719105.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 12738433000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 12582785000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 19894000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 17220487000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 15078781000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 2816085000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 12738433000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 2039012000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 4482054000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 10173711000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 2380307000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
ORCHPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 4945029000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 331569000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 2072670000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 50656627.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic EPS: -2.49
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 1431466000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 90294000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 90294000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 50656627.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: -2.49
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -126135000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — EBIT: -89687000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — EBITDA: 607000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 641204000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 31777000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 31777000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income: -126135000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -126135000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -126135000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -126135000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -126135000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -126135000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -31777000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -31777000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 71734000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized Income: -55008000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Income: 309635000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 2072670000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -328195000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 71127000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Pretax Income: -121464000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 1431466000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 90294000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -71127000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 1763035000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -71127000.00
ORCHPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -71127000.00
ORCHPHARMA.NS income_statement (annual, 2026-03-31) — +Operating Expense: 1269219000.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 297460000.00
ORCHPHARMA.NS income_statement (annual, 2026-03-31) — +Total Revenue: 8113273000.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 2376073000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 2299025000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 2299025000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 2638711000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 2638711000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 562673000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 562673000.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 50704051.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 4.69
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 211068000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -3835810000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 51102000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 51102000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 507191000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 507191000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 70080000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 70080000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 840740000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 840740000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Inventory: 699601000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -221157000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Payable: 61039000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -140942000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: 521444000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -140988000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock: 507191000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 507191000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 12877850000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 12877850000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 3405211000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 3405211000.00
ORCHPHARMA.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 5258753000.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 1513568000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Assets: 6838986000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 6838986000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 3854000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 3854000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt: 297510000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 297510000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 301364000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 301364000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Deferred Taxes Assets: 2928000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Deferred Taxes Assets: 2928000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 2789701000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 2789701000.00
ORCHPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 1318000.00
ORCHPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 1318000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation: 354527000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 354527000.00
ORCHPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 354527000.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 88678000.00
ORCHPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 354527000.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 88678000.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 50704051.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 4.69
ORCHPHARMA.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 205470000.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 237802000.00
ORCHPHARMA.NS income_statement (annual, 2026-03-31) — EBIT: 342754000.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — EBIT: 258780000.00
ORCHPHARMA.NS income_statement (annual, 2026-03-31) — EBITDA: 697281000.00
ORCHPHARMA.NS income_statement (quarterly, 2026-03-31) — EBITDA: 347458000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — End Cash Position: 70080000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 1699803000.00
ORCHPHARMA.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -2823857000.00